Zydus Wellness: Maintain ‘buy’; TP unchanged at Rs 2,500

By: |
May 13, 2021 4:15 AM

Nutralite (75% is B2B business) also continued to witness sequential recovery.

Valuation and risks: We increase our earnings estimates by ~3% for FY22-23E.Valuation and risks: We increase our earnings estimates by ~3% for FY22-23E.

Strong growth momentum continues: Reported revenue /ebitda/ recurring PAT grew by 24%/39% /85% YoY driven by strong performance of double-digit growth in most of the consumer brands (double-digit growth in 2-year CAGR as well) except for Glucon D as the summer season was delayed. Nutralite (75% is B2B business) also continued to witness sequential recovery.

Margins expanded despite higher ad-spends driven by input cost benefit and operating leverage: Gross margin expanded 70bps to 54.6% driven by better product mix and benefits of deflationary milk prices. However, reported ebitda margin expanded higher by 260bps to 24% despite significant step-up in ad-spends (+450bps YoY; +65% YoY) driven by operating leverage — lower staff cost (-300bps) and other expenses (-140bps) due to cost saving initiatives. Management stated that they are on track to reach ebitda margins of 20% by FY22.

Highlights: 1) OCF / FCF grew by 11% / 14% to Rs 2.9billion /Rs 2.7billion, 2) working capital days increased by 21 days largely due to higher inventory days and lower creditor days, 3) Direct reach increased to 0.55mn outlets, 4) E-commerce grew ~3x in FY21 (~3.6 of domestic revenues), 5) Exports business grew by ~2x in FY21 (~3% of overall business), and 6) launched 11 new products in FY21 (NPD now contributes ~3.5% of business).

Valuation and risks: We increase our earnings estimates by ~3% for FY22-23E. We model revenue /ebitda / PAT CAGR of 11% / 19% / 36% over FY21-23E – net profit likely to grow ahead of revenue and ebitda driven by deleveraging of balance sheet. Maintain ‘buy’ with a DCF-based unchanged target price of Rs 2,500. At our target price, the stock will trade at 35x P/E multiple Mar-23E.

Key downside risks are delays or failures in new product development or inability to expand distribution.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Gold Price Today, 23 June 2021: Yellow metal gains as US Fed won’t raise rates; MCX silver up
2Stocks to buy: 15,670-15,800 key trading area for Nifty, F&O expiry major trigger; TCS, Tata Motors may rally
3SGX Nifty moves up 68 pts, Sensex, Nifty may open in green; India Pesticides IPO, among key things to watch